Avita Medical Inc.

Seven analysts raised their consolidated price target from $5.50 to $12, citing renewed confidence in RECELL adoption, organic revenue momentum, and Q1 2026 being AVITA Medical's highest revenue quarter since mid-2024, suggesting a credible commercial recovery is underway.

Even optimistic analysts acknowledge that RECELL adoption still needs to play out in practice. If physician uptake slows or plateaus, the case for higher valuation multiples could weaken significantly, and any execution shortfall against elevated guidance would trigger a reassessment of the growth profile.

Analysts point to adequate avenues for working capital needs and an improved cash position, which they see as reducing near-term funding concerns. Simply Wall St's analysis also argues there is no immediate cause for alarm regarding AVITA Medical's cash burn situation.

Simply Wall St flags that AVITA Medical has less than one year of cash runway, negative shareholders' equity, and a history of shareholder dilution, representing serious near-term financial risks that could impair operational execution and force additional capital raises.

Analysts project earnings to grow at 57.24% per year, and the stock is assessed as trading at 56.7% below estimated fair value, with a Price-to-Sales ratio of just 1.6x versus a peer average of 16.7x, suggesting the market is significantly undervaluing the company's long-term earnings potential.

The consensus breakeven date for AVITA Medical has been pushed back from 2027 to 2028, reflecting deteriorating near-term profitability expectations. Expected net profit margin was also slashed from 34.27% to 7.54%, signaling that the path to sustained profitability is far more uncertain than previously modeled.